Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 infection of human cortical cells is influenced by the interaction between aneuploidy and biological sex, insights from a Down syndrome in vitro model

  • Lioudyno, Maria I.
  • Sevrioukov, Evgueni A.
  • Olivarria, Gema M.
  • Hitchcock, Lauren
  • Javonillo, Dominic I.|||0000-0002-4243-8372
  • Campos, Sydney M.
  • Rivera, Isabel
  • Wright, Sierra T.
  • Head, Elizabeth|||0000-0003-1115-6396
  • Fortea, Juan|||0000-0002-1340-638X
  • Wisniewski, Thomas|||0000-0002-3379-8966
  • Cuello, AC.|||0000-0003-2143-2745
  • Do Carmo, Sonia
  • Lane, Thomas E.
  • Busciglio, Jorge
Individuals with Down Syndrome (DS) represent one of the most susceptible populations for developing severe COVID-19, and a unique human genetic condition for investigating molecular mechanisms underlying susceptibility of neurologically vulnerable individuals to SARS-CoV-2 infection. Human Chromosome-21 (HSA21) triplication in DS causes global transcriptional deregulation, affecting multiple genes that may directly (e.g., TMPRSS2) or indirectly influence the SARS-CoV-2 entry into central nervous system (CNS) cells. The anti-viral immune response may also be altered in cells with trisomy-21 (T21) due to triplication of genes encoding for several interferon receptor subunits and interferon-stimulated genes (ISGs). Here, we demonstrate that human cells derived from fetal cortical specimens and maintained in primary cultures are susceptible to infection with a molecular clone of vesicular stomatitis virus engineered to express the Spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and to authentic SARS-CoV-2. The level of SARS-CoV-2 infectivity in cultures originated from different cortical specimens varied, seemingly depending on ploidy and chromosomal sex of the cells. We confirmed the presence of ACE2 and TMPRSS2 in cultures and found that XY T21 group had the highest TMPRSS2 mRNA levels, which was associated with increased infectivity in XY-compared to XX T21 cultures. The XX T21 cultures exhibited elevated expression of several ISGs (MX1, STAT1, and STAT2) which was associated with lower infectivity. The comparisons of postmortem aged brain specimens revealed reduced ACE2, TMPRSS2, but elevated STAT2 protein levels in individuals with DS and Alzheimer's disease (DS-AD) compared to control and Alzheimer's disease (AD) group. Collectively, these results suggest multifactorial regulation of SARS-CoV-2 infectivity in cortical cells that involves ploidy, chromosomal sex, and the expression of genes implicated in regulation of virus entry and anti-viral response as contributing factors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease

  • Wagemann, O.
  • Nübling, G.
  • Martínez-Murcia, F.J.
  • Wlasich, E.
  • Loosli, S.V.
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Stockbauer, A.
  • Prix, C.
  • Katzdobler, S.
  • Petrera, A.
  • Hauck, S.M.
  • Fortea, Juan|||0000-0002-1340-638X
  • Romero-Zaliz, R.
  • Jiménez-Mesa, C.
  • Górriz Sáez, J.M.
  • Höglinger, G.
  • Levin, J.
INTRODUCTION: Adults with Down syndrome (DS) show increased risk for Alzheimer's disease (AD) due to the triplication of chromosome 21 encoding the amyloid precursor protein gene. Further, this triplication possibly contributes to dysregulation of the immune system, furthering AD pathophysiology. METHODS: Using Olink Explore 3072, we measured ∼3000 proteins in plasma from 73 adults with DS and 15 euploid, healthy controls (HC). Analyses for differentially expressed proteins (DEP) were carried out, and pathway and protein network enrichment using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and STRING database was investigated. Within DS, the LASSO (least absolute shrinkage and selection operator) feature selection was applied. RESULTS: We identified 253 DEP between DS and HC and 142 DEP between symptomatic and asymptomatic DS. Several pathways regarding inflammatory and neurodevelopmental processes were dysregulated in both analyses. LASSO feature selection within DS returned 15 proteins as potential blood markers. DISCUSSION: This exploratory proteomic analysis found potential new blood biomarkers for diagnosing DS-AD in need of further investigation. Highlights: Inflammatory pathways are dysregulated in symptomatic versus asymptomatic DS. NFL and GFAP are confirmed as powerful biomarkers in DS with clinical and/or cognitive decline. Further circulating proteins were identified as potential blood biomarkers for symptomatic DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Aranha, Mateus|||0000-0001-9594-292X
  • Pérez-González, R.
  • Serrano-Requena, S.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Chiva-Blanch, Gemma|||0000-0001-6093-0160
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Busciglio, J.
  • Wisniewski, Thomas M.
  • Carmo, S.D.
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Muñoz, L.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Lleó, Alberto|||0000-0002-2568-5478
  • Cuello, AC.|||0000-0003-2143-2745
  • Fortea, Juan|||0000-0002-1340-638X
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Iulita, M. Florencia|||0000-0002-3360-4498
BACKGROUND: In Down syndrome (DS) and Alzheimer's disease (AD), nerve growth factor precursor protein (proNGF) accumulates in the brain. However, its non-invasive detection using neuron-derived extracellular vesicles (NDEVs) from plasma remains unexplored. METHODS: We included 139 adults with DS (45 asymptomatic [aDS], 94 symptomatic for AD [sDS]) and 37 healthy controls. NDEVs were isolated from plasma. ProNGF and tetraspanin (CD81) were quantified by enzyme-linked immunosorbent assay. We assessed proNGF/CD81 changes with age, along the AD continuum (aDS and sDS), and associations with cerebrospinal fluid (CSF), plasma biomarkers, episodic memory, and basal forebrain volume. RESULTS: In DS, proNGF/CD81 levels increased with age and were higher in NDEVs from asymptomatic and symptomatic individuals compared to controls, with the highest levels in the symptomatic group. ProNGF correlated with CSF phosphorylated tau (p-tau)181, plasma p-tau217, neurofilament light chain, and episodic memory. DISCUSSION: ProNGF/CD81 levels in NDEVs increase along the AD continuum in DS and parallel tau pathology, indicating the potential as a promising biomarker for monitoring disease progression in plasma. Highlights: Nerve growth factor precursor protein (ProNGF)/tetraspanin (CD81) ratio increased in the third decade of life, 20 years before Alzheimer's disease (AD) symptom onset in Down syndrome (DS). proNGF/CD81 concentrations were significantly higher in individuals with DS compared to controls and were notably elevated in individuals with DS and symptomatic AD compared to asymptomatic AD. proNGF/CD81 concentrations were associated with tau pathology and neuronal injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Sex-related differences in genetically determined Alzheimer's disease

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Wagemann, O.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Levin, J.
  • Fortea, Juan|||0000-0002-1340-638X
We reviewed the literature on sex differences in genetically determined Alzheimer's disease (AD), focusing on autosomal dominant AD (ADAD), Down syndrome-associated AD (DSAD), and APOE4 homozygosity, particularly regarding disease penetrance, symptom onset and clinical progression, and trajectories for markers of amyloidosis (A), tau pathology (T) and neurodegeneration (N). Data suggests that sex differences in disease penetrance, symptom onset, and AT(N) biomarker trajectories are typically subtle for genetically determined AD populations. Noteworthy exceptions, such as increased neurodegeneration in later stages of the disease in females while similar cognitive outcomes, suggest a potential differential cognitive reserve that warrants further investigation. Additionally, the interaction between APOE genotype and sex reveals complex and multifaceted effects in DSAD, with potential implications for ADAD that remain underexplored. The smaller sex differences observed compared to sporadic AD offer insights into the different underlying disease mechanisms in genetically determined AD populations. Future research should prioritize sex-specific investigations in genetically determined AD, focusing on refining methodologies. This includes prioritizing longitudinal designs, adjustment for key confounders, and adherence to sex-specific guidelines.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study

  • Martín-Peláez, Sandra
  • Serra-Majem, Lluis
  • Cano-Ibáñez, Naomi
  • Martínez-González, Miguel Ángel
  • Salas-Salvadó, Jordi
  • Corella, Dolores
  • Lassale, Camille
  • Martínez, Jose Alfredo
  • Alonso-Gómez, Ángel M.
  • Wärnberg, Julia
  • Vioque, Jesús
  • Romaguera, Dora
  • López-Miranda, José
  • Estruch, Ramón
  • Tinahones, Francisco J.
  • Lapetra, José
  • Fernández-Aranda, Fernando
  • Bueno-Cavanillas, Aurora
  • Tur, Josep A.
  • Martín, Vicente
  • Pintó, Xavier
  • Delgado-Rodríguez, Miguel
  • Matía, Pilar
  • Vidal, Josep
  • Vázquez, Clotilde
  • Daimiel, Lidia
  • Ros, Emili
  • Toledo, Estefanía
  • Nishi, Stephanie K.
  • Sorli, Jose V.
  • Malcampo, Mireia
  • Zulet, M. Ángeles
  • Moreno-Rodríguez, Anaí
  • Cueto-Galán, Raquel
  • Vivancos-Aparicio, Diego
  • Colom, Antoni
  • García-Ríos, Antonio
  • Casas, Rosa
  • Bernal-López, M. Rosa
  • Santos-Lozano, Jose Manuel
  • Vázquez, Zenaida
  • Gómez-Martínez, Carlos
  • Ortega-Azorín, Carolina
  • Del Val, Jose Luís
  • Abete, Itziar
  • Goikoetxea-Bahon, Amaia
  • Pascual, Elena
  • Becerra-Tomás, Nerea
  • Chillarón, Juan J.
  • Sánchez-Villegas, Almudena
[eng] Background: Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55–75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial. Methods and findings: Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240–279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively). Conclusions: Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  • Valle Tamayo, Natalia
  • Aranha, Mateus
  • Pérez-González, Rocío
  • Serrano-Requena, Sara
  • Videla, Laura
  • Barroeta, Isabel
  • Benejam, Bessy
  • Chiva-Blanch, Gemma
  • Jiménez, Amanda
  • Busciglio, Jorge
  • Wisniewski, Thomas
  • Do Carmo, Sonia
  • Álvarez-Sánchez, Esther
  • Muñoz, Laia
  • Bejanin, Alexandre
  • Belbin, Olivia
  • Alcolea, Daniel
  • Carmona-Iragui, María
  • Lleó, Alberto
  • Cuello, A. Claudio
  • Fortea, Juan
  • Dols-Icardo, Oriol
  • Iulita, M. Florencia
[Background] In Down syndrome (DS) and Alzheimer's disease (AD), nerve growth factor precursor protein (proNGF) accumulates in the brain. However, its non-invasive detection using neuron-derived extracellular vesicles (NDEVs) from plasma remains unexplored, [Methods] We included 139 adults with DS (45 asymptomatic [aDS], 94 symptomatic for AD [sDS]) and 37 healthy controls. NDEVs were isolated from plasma. ProNGF and tetraspanin (CD81) were quantified by enzyme-linked immunosorbent assay. We assessed proNGF/CD81 changes with age, along the AD continuum (aDS and sDS), and associations with cerebrospinal fluid (CSF), plasma biomarkers, episodic memory, and basal forebrain volume., [Resultr] In DS, proNGF/CD81 levels increased with age and were higher in NDEVs from asymptomatic and symptomatic individuals compared to controls, with the highest levels in the symptomatic group. ProNGF correlated with CSF phosphorylated tau (p-tau)181, plasma p-tau217, neurofilament light chain, and episodic memory., [Discussion] ProNGF/CD81 levels in NDEVs increase along the AD continuum in DS and parallel tau pathology, indicating the potential as a promising biomarker for monitoring disease progression in plasma., The authors thank all study participants and caregivers for their support and dedication. The authors acknowledge the help of Soraya Torres, Shaimaa El Bounasri El Bennadi, and Oriol Sanchez Lopez for sample handling and preparation. The authors also recognize the collaboration of José Amable Bernabé from the ICTS “NANBIOSIS,” unit 6 (CIBER in Bioengineering, Biomaterials & Nanomedicine) at the Barcelona Materials Science Institute, and Marti de Cabo Jaume from the Electron Microscopy Unit at Universitat Autonoma de Barcelona. The authors also extend our appreciation to the Fundació Catalana Síndrome de Down (https://fcsd.org/) for their overall support, and to Tania Martínez, Cristina Pastor, and Ana Sebastián for administrative assistance, as well as Aida Sanjuan and Mireia Carreras for nursing support. This study was funded by Jerome Lejeune Foundation (France), through projects Project #1941 to MFI and #1913 to MCI and the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects PI21/01395 (and associated FI22/00077 to N.V.T. and O.D.I.) and PI24/01087 to O.D.I.; INT21/00073, PI20/01473 and PI23/01786 to J.F., CP20/00038 and PI22/00307 to A.B., PI18/00435 to D.A., PI20/01330 to A.L.) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partially jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund (ERDF/ESF), ‘A way to make Europe’/‘Investing in your future’. This study was also supported by the Jerome Lejeune Foundation #51 (PDC-2023-51) to O.D.I. This work was also supported by the National Institutes of Health grants (R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543 to J.F. and P30AG066512, R01AG087002 and P01AG060882 to T.W.), the Department de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca I Innovació en Salut (SLT006/17/00119 to J.F.; SLT002/16/00408 to A.L. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to J.F.) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to J.F.) also supported this work. The Alzheimer Association also participated in the funding of this work (AARG-22-923680 to A.B. and AARF-22-924456 to ODI)., Peer reviewed